Artificial intelligence to speed diagnosis, switching complement therapies, ravulizumab during pregnancy, and iptacopan ...

Credit: Novartis. The approval was based on data from the phase 3 APPLY-PNH trial. Health care providers who prescribe Fabhalta must enroll in the Fabhalta REMS. The Food and Drug Administration (FDA) ...

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...

(RTTNews) - Swiss drug major Novartis AG (NVS) Wednesday announced that the U.S. Food and Drug Administration or FDA has approved its Fabhalta (iptacopan) as the first oral monotherapy to treat adults ...

The U.S. FDA has approved Novartis AG’s Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disease that impairs blood cell production.

Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...